Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Class H Shares 06990
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$487.00
- Day Range
- HK$459.00–500.00
- 52-Week Range
- HK$345.20–581.00
- Bid/Ask
- HK$471.20 / HK$472.20
- Shares Outstanding
- 239.02M
- Market Cap
- HK$112.87B
- Volume/Avg
- 349,283 / 907,216
Key Statistics
- Price/Earnings (Normalized)
- 442.12
- Price/Sales
- 48.78
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,300
- Website
- https://www.kelun-biotech.com
Valuation
|
Metric
|
06990
|
|---|---|
Price/Earnings (Normalized) | 442.12 |
Price/Book Value | 18.44 |
Price/Sales | 48.78 |
Price/Cash Flow | 194.28 |
Price/Earnings
06990
Financial Strength
|
Metric
|
06990
|
|---|---|
Quick Ratio | 5.97 |
Current Ratio | 6.34 |
Interest Coverage | 10.58 |
Quick Ratio
06990
Profitability
|
Metric
|
06990
|
|---|---|
Return on Assets (Normalized) | 5.54% |
Return on Equity (Normalized) | 6.65% |
Return on Invested Capital (Normalized) | 6.49% |
Return on Assets
06990
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|CNxsrF | LOCK|gD>v< | $128B | |||
| Moderna Inc
MRNA
| LOCK|kX^@$Dn | LOCK|%tb | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$S%Ns?> | LOCK|kk#d | $76B | |||
| argenx SE ADR
ARGX
| LOCK|CpB#@>T | LOCK|X! | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Vn^M!?@ | LOCK|lq | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|%M#S%q& | LOCK|#SKG | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|s^^Gt>d# | LOCK|%<Ml | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|RMw$>T | LOCK|YSW | $24B | |||
| Incyte Corp
INCY
| LOCK|>Y>xX^ | LOCK|#x | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Px?!HL | LOCK|xt | $15B |
United States